New hope for breast cancer patients who Don't respond to standard therapy
NCT ID NCT07528898
First seen Apr 17, 2026 · Last updated May 22, 2026 · Updated 10 times
Summary
This study tests a personalized approach for people with HER2-positive breast cancer. After two cycles of standard treatment, those whose tumors shrink less than 40% will switch to a new drug combo (SHR-A1811 plus pertuzumab) for four more cycles before surgery. The goal is to see if this switch helps more patients achieve a complete response, meaning no cancer remains in the breast or lymph nodes at surgery. About 100 adults aged 18-70 with stage II or III breast cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.